Ekspresija faktora-1 aktivacije proteaza apoptoze u adenoidnom cističnom karcinomu pljuvačnih žlezda i njegov kliničkopatološki značaj
Sažetak
Uvod/Cilj. Faktor 1 aktivacije proteaza apoptoze (Apaf-1) je ključni molekul u unutrašnjem ili mitohondrijskom putu apoptoze. Različita patološka stanja, kao na primer maligniteti, neurodegenerativne bolesti, moždani udar, povezuju se sa poremećajem unutrašnjeg puta apoptoze. Cilj rada bio je da se analizira imunohistohemijska ekspresija Apaf-1 u ćelijama adenoidnog cističnog karcinoma (ACC) pljuvačnih žlezda i njegova korelacija sa kliničko-patološkim parametrima obolelih (pol, starost, lokalizacija, histološki tip i ukupno preživljavanje). Metode. U studiji su korišćeni parafinski uzorci ACC pljuvačnih žlezda 50 obolelih muškaraca i žena, prosečne starosti 58 godina. Korišćena je tehnika mikrotkivnog niza (tissue microarrays – TMA block). Mikrotkivni preseci, debljine 5 μm, bojeni su streptavidin-biotin imunohistohemijskom tehnikom primenom primarnog antitela specifičnog za Apaf-1 (Leica Biosystems, Newcastle, UK). Preparati su analizirani svetlosnim mikroskopom (Olympwus type BH-2). Na osnovu prikupljenih podataka kreirana je baza podataka u SPSS softveru 22.0 (SPSS Inc., Chicago, ILL, USA) koji je korišćen za dalju statističku analizu. Statistička analiza podataka obuhvatala je metodu deskriptivne i analitičke
(inferencijalne) statistike. Rezultati. Rezultati imunohistohemijske analize ekspresije Apaf-1 u uzorcima bolesnika sa ACC pljuvačnih žlezda upoređeni su sa njihovim kliničko-patološkim parametrima. Ekspresija Apaf-1 nije pokazala statističku značajnost u odnosu na pol bolesnika (p = 0,552), starost (p = 0,106), histološki tip tumora (p = 0,654) i lokalizaciju ACC u pljuvačnim žlezdama (p = 0,486). Nije primećena statistički značajna korelacija između ekspresije Apaf-1 i preživljavanja bolesnika sa ACC (p = 0,340, Log-Rank test). Zaključak. U odnosu na ACC, ekspresija Apaf-1 nije u korelaciji sa kliničko-patološkim parametrima bolesnika (pol, starost, lokalizacija, histološki tip i ukupno preživljavanje). Zato verujemo da se Apaf-1 ne može smatrati nezavisnim prognostičkim faktorom za tok i ishod ACC pljuvačnih žlezda.
Reference
Rossi DE, Baloch Z, Pusztaszeri M, Faquin CW. The Milan Sys-tem for Reporting Salivary Gland Cytopathology (MSRSGC): an ASC-IAC–sponsored system for reporting salivary gland fi-ne-needle aspiration. J Am Soc Cytopathol 2018; 7(3): 111‒8.
Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol He-matol 2010; 74(2): 134‒48.
Ishida E, Ogawa T, Rokugo M, Ishikawa T, Wakamori S, Ohkoshi A, et al. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up. Head Face Med 2020; 16(1): 14.
Xu L, Li L, Zhang J, Cai W, Zhao S, Liu S. Accumulated cyto-toxicity of CDK inhibitor dinaciclib with first-line chemo-therapy drugs in salivary adenoid cystic carcinoma cells. Odon-tology 2020; 108(2): 300‒11.
Shizhi H, Pingdong L, Qi Z, Lizhen H, Zhenkun Y, Zhigang H, et al. Clinicopathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands: A clinical analysis of 130 cases. Am J Otolaryngol 2017; 38(2): 157‒62.
Liu HX, Wu M, Sun YM, Han FY, Liu YF, Zhang GZ. Prog-nostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma. Int J Clin Exp Pathol 2017; 10(7): 7882‒9.
Acharyaa S, Annehosurb V, Hallikeri K, Shivappaa KS. Adenoid cystic carcinoma of the sublingual salivary gland: Case report of a rare clinical entity. J Oral Maxillofac Surg Med Pathol 2016; (28): 88–94.
Thierauf J, Ramamurthy N, Jo YV, Robinson H, Frazier PR, Gonzalez J, et al. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist 2019; 24(10): 1356–67.
Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S, et al. The TRAIL to cancer therapy: Hindrances and poten-tial solutions. Crit Rev Oncol Hematol 2019; 143: 81‒94.
Gilmore A, King L. Emerging approaches to target mitochon-drial apoptosis in cancer cells. F1000Res 2019; 8: F1000 Fac-ulty Rev‒1793.
Noori AR, Hosseini ES, Nikkhah M, Hosseinkhani S. Apopto-some formation upon overexpression of native and truncated Apaf-1 in cell-free and cell-based systems. Arch Biochem Bio-phys 2018; 642: 46‒51.
Dorstyn L, Akey WC, Kumar S. New insights into apoptosome structure and function. Cell Death Differ 2018; 25(7): 1194–208.
Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci 2010; 123(Pt 19): 3209‒14.
Acehan D, Jiang X, Morgan DG, Heuser EJ, Wang X, Akey WC. Three-dimensional structure of the apoptosome: implications for assembly procaspase-9 binding and activation. Mol Cell 2002; 9(2): 423–32.
Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expres-sion in human cutaneous melanomas. Br J Cancer 2004; 91(6): 1089–95.
Leo C, Richter C, Horn LC, Schütz A, Pilch H, Höckel M. Ex-pression of Apaf-1 in cervical cancer correlates with lymph node metastasis but not with intratumoral hypoxia. Gynecol Oncol 2005; 97(2): 602‒6.
Zlobec I, Minoo P, Baker K, Haegert D, Khetani K, Tornillo L, et al. Loss of APAF-1 expression is associated with tumour pro-gression and adverse prognosis in colorectal cancer. Eur J Cancer 2007; 43(6): 1101‒7.
Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, et al.. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2007; 14(12): 3453‒9.
Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P. Expres-sion and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspa-se-9 is associated with poor prognosis. Int J Cancer 2010; 127(4): 873‒80.
Yamamura M, Sato Y, Takahashi K, Sasaki M, Harada K. The cyclin‑dependent kinase pathway involving CDK1 is a poten-tial therapeutic target for cholangiocarcinoma. Oncol Rep 2020; 43(1): 306‒17.
Geng X, Sun YY, Fu JJ, Cao L, Li Y. Role of miR-155-5p ex-pression and its involvement in apoptosis-related factors in thyroid follicular carcinoma. J Clin Pharm Ther 2020; 45(4): 660‒5.